Taken together, the proteomic analysis of the clinical CSF samples reveals that acitretin only mildly affected the CSF protein composition of AD patients and demonstrates that the acitretin‐induced ADAM10 activation is presumably moderate in vivo, as only few ADAM10 substrates showed altered protein levels in CSF. Here, ADAM10 is linked to Alzheimer disease.